Biogen Idec Inc (BIIB) 329.24 $BIIB
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec
M2 - Fri Sep 19, 6:04AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company's collaboration with Biogen Idec. The XTEN technology is proprietary to Amunix Operating, Inc.. Biogen Idec and Amunix signed a worldwide license agreement in April 2014. Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to include the rFVIIIFc-XTEN-vWF fusion molecule in the collaboration. Sobi is required to make a payment to Biogen Idec to include this program in the collaboration agreement.
Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:50PM CDT
On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART).
Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:35PM CDT
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.
Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:10PM CDT
Alnylam Pharmaceuticals (ALNY) intends to file a clinical trial application for ALN-CC5 by year end.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:51AM CDT
Repros Therapeutics Inc. (RPRX) saw a big move last session,continuing the recent downtrend for RPRX, as the stock is now down more than 11.5% in the past one-month time frame.
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders
Business Wire - Wed Sep 17, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.01% Loss
Comtex SmarTrend(R) - Mon Sep 15, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $315.71 to a high of $323.97. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $321.11 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec
M2 - Fri Sep 19, 6:04AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company's collaboration with Biogen Idec. The XTEN technology is proprietary to Amunix Operating, Inc.. Biogen Idec and Amunix signed a worldwide license agreement in April 2014. Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to include the rFVIIIFc-XTEN-vWF fusion molecule in the collaboration. Sobi is required to make a payment to Biogen Idec to include this program in the collaboration agreement.
Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:50PM CDT
On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART).
Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:35PM CDT
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.
Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:10PM CDT
Alnylam Pharmaceuticals (ALNY) intends to file a clinical trial application for ALN-CC5 by year end.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:51AM CDT
Repros Therapeutics Inc. (RPRX) saw a big move last session,continuing the recent downtrend for RPRX, as the stock is now down more than 11.5% in the past one-month time frame.
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders
Business Wire - Wed Sep 17, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.01% Loss
Comtex SmarTrend(R) - Mon Sep 15, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $315.71 to a high of $323.97. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $321.11 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
